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BACKGROUND: The study aimed to compare the tolerability and efficacy of gefitinib combined with
chemotherapy agents versus chemotherapy alone for the treatment of epidermal growth factor receptor
(EGFR)–mutated lung adenocarcinoma in heavily pretreated patients. METHODS: The study was designed as a
matched-pair case-control investigation to minimize intergroup heterogeneity. Patients were stratified into gefitinib
plus chemotherapy and chemotherapy alone groups with matching for sex, age, ECOG performance status,
progress-free survival (PFS) from previous EGFR tyrosine kinase inhibitor treatment, EGFR mutation types, and
tumor metastasis status. RESULTS: Sixty-six patients were selected from our database using the matched-pair
method. The median age was 61 years (95% confidence interval, 57-65 years). During a follow-up period of 14.5
months on average, the overall response rates of the gefitinib-integrated and chemotherapy alone groups were
9.1% and 6.5%, respectively (P N .05), whereas the corresponding disease-control rates were 39.4% and 30.3%,
respectively (P N .05). No statistically significant differences in PFS (median, 4.2 vs 3.3 months; P= .06) and overall
survival (median, 10.4 vs 7.9 months; P = .44) were observed between two groups. The 6-month survival rates of
the gefitinib-integrated and chemotherapy alone groups were 21.2% and 12.1%, respectively (P b .05). Side
effects were mild, and all treatments were well tolerated. CONCLUSIONS: Our results indicated that gefitinib-
integrated therapy offered a trend to better PFS and an improved 6-month survival rate in heavily pretreated
patients with metastatic EGFR-mutated lung adenocarcinoma. All treatments were well tolerated. Future
prospective studies are warranted to confirm our findings.
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Platinum-based chemotherapy is the standard first-line therapeutic
regimen for advanced non–small cell lung cancer (NSCLC) [1–4]. In
cases of disease progression, single-agent regimens such as docetaxel or
pemetrexed are often provided as second-line chemotherapy [5–7].
Since its development approximately 10 years ago, epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment has
been another milestone in the management of NSCLC. For patients
with EGFR-mutated lung adenocarcinoma, EGFR-TKIs, such as
gefitinib, erlotinib, and icotinib, have demonstrated promising
therapeutic efficacy. These agents have been used as first- or
second-line therapy in patients with EGFR-mutated lung adenocar-
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with EGFR-mutated advanced lung adenocarcinoma with initial
response to chemotherapy or subsequent EGFR-TKI eventually
developed disease progression. As the mechanisms of such acquired
resistance such as T790M and D761Y mutations are under
investigation and remain poorly understood [18], additional
treatment options for these patients whose general conditions are
adequate remain necessary. Because limited data are available on the
issue, such additional treatments are controversial. Although current
treatment of TKI-resistant NSCLC is chemotherapy, many novel
strategies are under investigation, including the continuation beyond
progression of EGFR-TKIs or the usage of a different TKI [19–21].
Chaft et al. [22] reported incidences of disease flare after
discontinuation of TKI in patients with EGFR-mutant lung cancer
and acquired resistance to erlotinib or gefitinib. The data available
strengthen the hypothesis that at least two cell populations co-exist in
EGFR-mutated NSCLC: one remains sensitive to TKIs, whereas the
other one is resistant to TKIs [23]. Moreover, the 2014 National
Comprehensive Cancer Network guidelines suggest the continuation
beyond progression of EGFR-TKI combined with chemotherapy.
Therefore, treatment options for NSCLC patients who have failed
previous chemotherapy and the order of EGFR-TKI treatment
remain under discussion. Thus, the present study aimed to compare
the clinical outcomes of gefitinib plus chemotherapy and chemo-
therapy alone in heavily pretreated patients with EGFR-mutated
lung adenocarcinoma.Table 1. Baseline Patient Characteristics
Characteristics Integrated Chemotherapy P Value
Age, years .72
Median 62.09 61.06
95% CI 58.24-65.94 56.73-65.39
Sex
Male 12 12 1.00
Female 21 21
ECOG PS




Exon 19 deletion 27 26 .914





1-6 2 3 1.00
N6 31 30
Current chemotherapy
Docetaxel 26 26 1.00
Pemetrexed 7 7
PFSp, progress-free survival from previous TKI treatment.Materials and Methods
Patient Selection
The study was designed as a matched-pair case-control investiga-
tion to minimize intergroup heterogeneity. All patients selected from
our database had pathologically confirmed lung adenocarcinoma with
the following inclusion criteria: 1) EGFR-19/21 activation mutations,
2) previously receiving sequential use of chemotherapy and TKI, TKI
between two chemotherapy regimens, or chemotherapy between TKI
treatments followed by the reintroduction of TKI in heavily
pretreated patients, and 3) disease progression after previous
treatment, entered gefitinib-integrated regimen versus chemotherapy
alone. All patients provided informed consents previously to allow
their clinical data for research or publication purposes, which was
approved by our Institutional Ethics Committee. Clinical parameters
examined at the time of gefitinib-integrated or chemotherapy alone
treatments included age, sex, Eastern Cooperative Oncology Group
performance status (ECOG PS), EGFR mutation, prior systemic
chemotherapy, progression-free survival (PFS) from previous EGFR-
TKI treatment, and metastasis status.
Therapeutic Regimens
Patients were stratified into gefitinib plus chemotherapy and
chemotherapy alone groups. In the gefitinib-integrated group, oral
gefitinib was provided at a daily dose of 250 mg, except in
chemotherapy administration days. Treatment was continued until
disease progression, development of unacceptable toxicity, or patient's
refusal of therapy. Therapeutic regimens for patients in the
chemotherapy alone group were decided on the basis of their prior
treatments. Pemetrexed at 500 mg/m2 was administrated every 21
days if patients had previously received docetaxel or paclitaxel.
Otherwise, docetaxel at 75 mg/m2 was administered every 21 days.Response Evaluation
Response evaluation was conducted according to the Response
Evaluation Criteria in Solid Tumors version 1.0 guidelines [24] using
chest computed tomography scans. Because this study was not a
clinical trial, the evaluation timeline was not strictly predetermined.
Instead, a follow-up was conducted every 6 to 8 weeks on average.
Statistical Analysis
Treatment outcomes were evaluated as response rate, disease-
control rate, 6-month survival rate, PFS, and overall survival (OS).
PFS was defined as the time from the date of gefitinib-integrated or
chemotherapy treatment to that of disease progression or death of any
cause. OS was defined as the time from the date of treatment to that
of death. The Pearson chi-square test, Fisher exact test, and Kaplan-
Meier method were employed in this study [25]. A P value of b.05




A search in our database yielded 115 patients meeting all inclusion
criteria. Of these, 70 patients were treated with gefitinib and 45 with
gefitinib-integrated chemotherapy between January 2006 and June
2011. The matched-pair case-control method selected 66 patients
(33 pairs) for this study. The baseline characteristics of all included
patients are shown in Table 1. All variables (age, sex, ECOG PS, PFS
from previous EGFR-TKI treatment, EGFR mutation types, and
metastatic status) were well matched between the gefitinib-integrated
and chemotherapy alone groups with no statistically significant
differences observed.
Response and Toxicity
The response rates and observed toxicity are shown in Table 2. The
proportion of no disease progression at 6 months was more favorable
in the gefitinib-integrated group than in the chemotherapy alone
group. As patients had previously received EGFR-TKI, skin rash and
Table 2. Efficacy and Toxicity in Each Group
Response Integrated, % (n) Chemotherapy, % (n) P Value
Response rate 9.10% (3/33) 6.45% (2/33) .70
Disease control rate 39.39% (13/33) 30.30% (10/33) .60
No progression rate at 6 months 21.2% (7/33) 12.1% (4/33) .04
Toxicity
Grade 3 myelosuppression 12.1% (4/33) 12.1% (4/33) 1.00
Grade 2 skin rash 9% (3/33) 0 .238
Diarrhea ≤ 2 36.4% (10/33) 6.0% (2/33) .02
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prolonged and chronic EGFR-TKI usage. However, no grade 3
skin rash and diarrhea were recorded. Grade 2 skin reaction and
diarrhea might have been underestimated by both patients and
physicians as patients might have ignored such common toxicity-
related events and only records of mild diarrhea, dry skin, and itches
were noted in patients' medical history. We therefore concluded that
toxicity was mild, and both treatments were well tolerated.
PFS and OS
The median PFS of the gefitinib-integrated group was 4.15 months
[95% confidence interval (CI), 2.89–6.01], whereas that of the
chemotherapy alone group was 3.25 months (95% CI, 1.69–4.73;
hazard ratio, 0.806; P = .061; Figure 1A). The corresponding medianFigure 1. Kaplan-Meier curves for the OS (A) and PFS (B) of patients
treated with gefitinib-integrated regimen and chemotherapy alone.OS of the two groups was 10.36 months (95% CI, 9.15–12.24) and
7.9 months (95% CI, 6.00–11.35), respectively (hazard ratio, 0.872;
P = .44; Figure 1B). No significant differences in PFS and OS were
observed between the two groups.
Discussion
The role of EGFR-TKI when used in combination with chemother-
apy for NSCLC patients who are likely to respond to treatment in
first- or second-line setting is uncertain. Both gefitinib and erlotinib
have been extensively evaluated in phase III trials in combination with
standard chemotherapy for previously untreated NSCLC patients
who were not selected on the basis of EGFR mutation status [26–28].
EGFR-TKI combined with platinum-based therapy did not offer a
clinical benefit in response rate, time to progression, or survival.
However, despite no observable increase in survival, it remains
possible that clinical benefits in some patients were obscured in a
molecularly heterogeneous population. This was suggested by a
subset analysis of 274 patients to evaluate the survival impact of
mutations in EGFR and k-ras genes [29,30]. Patients with EGFR-
mutated tumors showed a trend toward improved PFS when erlotinib
was added to chemotherapy compared to chemotherapy alone. In
contrast, those with EGFR wild-type tumors tended to favor
chemotherapy alone. Wu et al. [31] reported that intercalated
combination of chemotherapy and erlotinib significantly prolonged
PFS in patient with advanced NSCLC. In a randomized phase II trial
conducted by Cancer and Leukemia Group B (CALGB 30406) [32],
181 patients with advanced lung adenocarcinoma were randomly
assigned to receive erlotinib alone or erlotinib plus chemotherapy
with carboplatin and paclitaxel. Tissue samples were analyzed for
EGFR mutation status in 164 patients (91%). The presence of an
EGFR mutation was associated with a statistically significant increase
in PFS compared to wild-type EGFR in both arms of the study (16 vs
3 months with erlotinib alone and 17 vs 5 months with erlotinib plus
chemotherapy). Similar differences were also observed in the OS (31
vs 18 months for erlotinib alone and 39 vs 14 months for erlotinib
plus chemotherapy). The addition of chemotherapy to an EGFR-TKI
did not result in an improved survival in patients whose tumors
expressed EGFR mutations.
The current treatment for TKI-resistant NSCLC is chemotherapy;
however, many patients require further management after chemo-
therapy, even TKI reintroduction that eventually fails. An incidence
of disease flare occurring after EGFR-TKI discontinuation might
predict a poor survival [32,33], which suggests that the continuation
beyond progression of EGFR-TKIs is a reasonable strategy. In this
matched-pair case-control study, the overall response rates in the
gefitinib-integrated and chemotherapy alone groups were 9.1% and
6.45%, respectively (P N .05). The corresponding disease-control
rates were 39.39% and 30.30%, respectively (P N .05). Such low
response rates might be owing to the acquired resistance to EGFR-
TKI and chemotherapy in heavily pretreated patients as they had all
received prior EGFR-TKI and one or two lines of chemotherapy.
Furthermore, the median OS (10.36 vs 7.9 months) and PFS (4.15 vs
3.25 months) did not significantly differ between the gefitinib-
integrated and chemotherapy groups. In our study enrolling
metastatic EGFR-mutated lung adenocarcinoma patients who had
failed prior EGFR-TKI and platinum-based chemotherapy, no
significant survival differences were observed between the gefitinib
plus chemotherapy and chemotherapy alone groups either. Although
this was a retrospective study rather than a clinical trial, the results
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employed, and selected patients were well matched between the two
groups regarding age, sex, ECOG PS, EGFR mutation, PFS from
previous EGFR-TKI treatment, and metastasis status. On the basis of
those limited data, several clinical trials were designed, including the
ongoing phase III randomized multicenter IMPRESS (A Study of
IRESSA Treatment Beyond Progression in Addition to Chemother-
apy Versus Chemotherapy Alone) trial to assess the safety and efficacy of
continuing gefitinib at 250 mg in addition to chemotherapy versus
chemotherapy alone in patients with EGFR-mutated NSCLC who have
progressed on first-line gefitinib. The results of this study are being expected.
Nevertheless, the present retrospective study cannot replace a
randomized clinical trial since selection bias might exist in other
unmeasured clinical factors and the evaluation timeline was not strictly
predetermined. Furthermore, the study cohort was limited, and other
important issues such as dose intensity, toxicity profiles, and treatment
compliance were not considered. In conclusion, to the best of our
knowledge, this is the first matched-pair case-control study that
evaluated and compared the outcomes between gefitinib-integrated
regimens and chemotherapy alone in EGFR-mutated lung adenocar-
cinoma patients who had failed prior EGFR-TKI and chemotherapy
treatments. Our analysis demonstrated that heavily pretreated patients
tended to achieve improved PFS and OS if treated with chemotherapy
plus gefitinib. Future prospective studies are warranted to elucidate any
differences in the efficacy, toxicity, dose intensity, and quality of life
between gefitinib-integrated treatment and chemotherapy alone.
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